タンパク薬剤のデリバリー発展動向

Evolving Approaches for Protein Drug Delivery

発行	Decision Resources, Inc.
出版日	2007年08月	商品コード	55716
ページ情報	英文 24 Pages
価格	こちらの商品の販売は終了いたしました。

概要
原文目次
関連レポート

当商品の販売は、2011年12月21日を持ちまして終了しました。

原文目次

Abstract

Introduction

Despite their remarkable success, protein drugs continue to suffer from important drawbacks, especially with respect to their delivery (subcutaneously or intravenously injected). Improvements in protein drug delivery will increase patient compliance and expand many drug markets. In addition, some new formulations may be patentable and can therefore extend a drug' s life cycle. For these reasons, pharmaceutical and biotechnology companies are researching and testing new delivery methods for protein drugs.

Get the Answers You Need to Shape Your Strategy

Although protein-based drugs have had great commercial success, they still suffer from signifi cant drawbacks, especially in the area of delivery. What are these drawbacks and what are the barriers for creating better protein drug delivery methods?
Many companies see the potential for improving the delivery methods for protein-based drugs. What companies are at the forefront of these improvements?
Researchers are approaching this opportunity from several different angles. Some companies are looking to modify drugs to improve pharmacokinetics while other companies are developing whole new technologies. What are the specifi c programs and development initiatives in place? What is the time line for the introduction of these improved drugs and/or delivery devices?

Scope

Milestones: Recent approval of two large-molecule drugs (Fortical and Exubera) that do not require injection show proof-of-principle that noninjected protein and peptide drugs can be developed successfully
Modifi cation and discovery of protein drugs: Pegylation, fusion proteins, amino acid substitution or omission.
Discovery and development of novel modifi ed proteins: novel pegylated protein drugs, novel fusion protein drugs, and novel bioengineered protein drugs
Novel delivery methods in development: oral delivery, buccal delivery, transdermal systems, subcutaneous implants, pulmonary delivery, intranasal delivery
Outlook: status of current programs, anticipated product launches, outlook for protein drug market.

Companies Mentioned in This Spectrum Report

Aegis Therapeutics
Aerogen
Alkermes
Altea Therapeutics
Alza
Amgen
Amylin Pharmaceuticals
Apogee Technology
Aradigm
Bayer
Biovitrum
Chrysalis Technologies
DOR BioPharma
Eli Lilly
Emisphere Technologies
Enzon
Generex
Georgia Tech Research Corporation
GlaxoSmithKline
Human Genome Sciences
Intranasal Therapeutics
Johnson & Johnson
Macrofl ux
MannKind
MicroCHIPS
Nautilus Biotech
Nektar Therapeutics
Novartis
Novo Nordisk
Pfi zer
Prolong Pharmaceuticals
Roche
Sandoz
Sanofi -Aventis
Schering-Plough
Spherics Pharmaceuticals
Syntonix Pharmaceuticals
Takeda
UCB Pharma
Unigene Laboratories
Upsher-Smith
Wyeth Pharmaceuticals

Strategic Considerations
- Stakeholder Implications
Introduction
Recent Milestones in Protein Drug Delivery
Modifi cation of Protein Drugs to Improve Pharmacokinetics
- Pegylation
- Fusion Proteins
- Amino Acid Substitution or Omission
Discovery and Development of Novel Modifi ed Proteins
- Novel Pegylated Protein Drugs
  - Nektar Therapeutics
  - Prolong Pharmaceuticals
- Novel Fusion Protein Drugs
  - Human Genome Sciences
  - Syntonix Pharmaceuticals
- Novel Bioengineered Protein Drugs
Transdermal Systems and Subcutaneous Implants
- Transdermal Delivery
  - Macrofl ux
  - Apogee Technology
  - Altea Therapeutics
  - Peptide Chaperone for Transdermal Delivery
  - MicroCHIPS
Oral and Buccal Delivery
- Unigene
- Emisphere Technologies
- Spherics Pharmaceuticals
- Generex
- DOR BioPharma
Pulmonary and Intranasal Delivery
- Pulmonary Insulin Products in Late-Stage Development
  - Alkermes/Eli Lilly
  - MannKind
  - Novo Nordisk
- Emerging Pulmonary and Intranasal Drug Delivery Systems
  - Chrysalis Technologies
  - Aegis Therapeutics
Outlook for Protein Drug Delivery